Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: Results of a 2-year prospective randomized multicenter study (INCOMIN). - Durelli,L.; Verdun,E.; Barbero,P. (Lancet, 2002)